Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-APOC3 in Adults With Severe Hypertriglyceridemia
NCT04720534Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 8
01
Overview
A Phase 2 trial of plozasiran in hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Started May 2021; status: completed.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT04720534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720534.